In 2024, the global hemoglobinopathy market (ヘモグロビン症市場) is estimated to be worth US$788.1 million, with a projected compound annual growth rate (CAGR) of 8.3% through 2034. By 2034, the market size is expected to exceed US$1,745.7 million. The rise of genetic testing has led to a significant shift in the hemoglobinopathy market towards personalized medication. Companies are leveraging this...
Arabic
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek